Files

870083.pdf (1.93 MB)

Document type

Article

Version

Published version

Publication date

2022-08-01

Publication license

cc-by (c) Bosch Amate, Xavier et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/216669

Treatment of granuloma annulare with tofacitinib

Journal Title

Authors

Director/Tutor

Additional contribution

Journal ISSN

Volume Title

Abstract

Granuloma annulare (GA) is a granulomatous, idiopathic, inflammatory skin disorder characterized by the formation of papules and plaques with annular and acral distribution. GA is often limited and self-resolving, but in some cases, it can be generalized and refractory to treatments. New advances in the pathophysiology of GA have favoured Janus kinase (JAK) inhibitors as a promising therapeutic option.1,2 Here, we report three cases of resistant generalized GA successfully treated with tofacitinib.

Related resource

https://doi.org/10.1111/ajd.13875

Subject

Malalties de la pell, Inhibidors enzimàtics, Resposta immunitària, Medicaments

Subject (English)

Skin diseases, Enzyme inhibitors, Immune response, Drugs

Citation

Collections

Articles publicats en revistes (Medicina)

Citation

BOSCH AMATE, Xavier, et al. Treatment of granuloma annulare with tofacitinib. Australasian Journal of Dermatology. 2022. Vol. 63, num. 3, pags. 400-403. ISSN 0004-8380. [consulted: 15 of October of 2026]. Available at: https://hdl.handle.net/2445/216669

Export metadata

JSON - METS

Share record